Masato Nakamura

Release and absorption characteristics of chlorphenesin carbamate sustained-release formulations: In vitro-in vivo and in vivo dog-human correlations

M. Akimoto, H. Ogata, A. Furuya, 1995 .

IN VITRO AND IN VIVO EVALUATION OF THE METABOLISM AND BIOAVAILABILITY OF ESTER PRODRUGS OF MGS0039 (3-(3,4-DICHLOROBENZYLOXY)-2-AMINO-6-FLUOROBICYCLO[3.1.0]HEXANE-2,6-DICARBOXYLIC ACID), A POTENT METABOTROPIC GLUTAMATE RECEPTOR ANTAGONIST

A. Nakazato, Masato Nakamura, Y. Kawakita, 2006, Drug Metabolism and Disposition.

Differences in cytochrome P450 forms involved in the metabolism of N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethylamine monohydrochloride (NE-100), a novel sigma ligand, in human liver and intestine.

K. Nagata, Y. Yamazoe, Masato Nakamura, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Metabolism of N,N-dipropyl-2-[4-methoxy-3-(2-phenyl-ethoxy)-phenyl]-ethyl-amine-monohydrochloride (NE-100), a novel sigma ligand: contribution of cytochrome P450 forms involved in the formation of individual metabolites in human liver and small intestine.

K. Nagata, Y. Yamazoe, Masato Nakamura, 2003, Drug metabolism and pharmacokinetics.

Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450.

X. Langlois, S. Chaki, A. Nakazato, 2004, European journal of pharmacology.

Synthesis, in vitro pharmacology, and structure-activity relationships of 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as mGluR2 antagonists.

S. Chaki, R. Yoshikawa, A. Nakazato, 2006, Bioorganic & medicinal chemistry.

Prodrugs of 3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (MGS0039): a potent and orally active group II mGluR antagonist with antidepressant-like potential.

S. Chaki, R. Yoshikawa, A. Nakazato, 2006, Bioorganic & medicinal chemistry.

Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists.

S. Chaki, R. Yoshikawa, A. Nakazato, 2004, Journal of medicinal chemistry.

METABOLISM AND DISPOSITION OF A POTENT GROUP II METABOTROPIC GLUTAMATE RECEPTOR AGONIST, IN RATS, DOGS, AND MONKEYS

A. Nakazato, Merryl D. Cramer, J. James, 2005, Drug Metabolism and Disposition.